Compare FINV & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FINV | WVE |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 668.1M | 673.9M |
| IPO Year | 2017 | 2015 |
| Metric | FINV | WVE |
|---|---|---|
| Price | $2.95 | $3.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 21 |
| Target Price | $5.62 | ★ $17.05 |
| AVG Volume (30 Days) | 866.5K | ★ 2.9M |
| Earning Date | 11-18-2026 | 10-27-2026 |
| Dividend Yield | ★ 10.55% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $3,704,000.00 |
| Revenue This Year | N/A | $48.79 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.87 | ★ N/A |
| Revenue Growth | N/A | ★ 149.43 |
| 52 Week Low | $2.80 | $3.04 |
| 52 Week High | $6.39 | $21.73 |
| Indicator | FINV | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 47.43 | 43.99 |
| Support Level | $2.89 | $3.04 |
| Resistance Level | $3.25 | $3.97 |
| Average True Range (ATR) | 0.15 | 0.24 |
| MACD | 0.02 | 0.05 |
| Stochastic Oscillator | 59.02 | 35.14 |
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.